HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hernán, M. A. Articles by Rodríguez, L. A. G. Search for Related Content PubMed PubMed Citation Articles by Hernán, M. A. Articles by Rodríguez, L. A. G.

Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

From the Department of Epidemiology (M.A.H., G.L.), Harvard School of Public Health, Boston, MA; and Centro Español de Investigación Farmacoepidemiológica (L.A.G.R.), Madrid, Spain.

Address correspondence and reprint requests to Dr. Miguel Hernán, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115; e-mail: miguel_hernan{at}post.harvard.edu

Animal and epidemiologic studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) decrease the incidence of Parkinson disease (PD). The authors studied 1,258 PD cases and 6,638 controls from the General Practice Research Database. The odds ratios (95% CI) for ever vs never use were 0.93 (0.80 to 1.08) for nonaspirin NSAIDs, 1.29 (1.05 to 1.58) for aspirin, and 1.16 (1.00 to 1.35) for acetaminophen. Nonaspirin NSAID use was associated with a higher risk in women and a lower risk in men.

Disclosure: The authors report no conflicts of interest.

Received September 15, 2005. Accepted in final form December 2, 2005.

This article has been cited by other articles:

				A Alonso, L A G. Rodriguez, G Logroscino, and M A Hernan Use of antidepressants and the risk of Parkinson's disease: a prospective study J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 671 - 674. [Abstract] [Full Text] [PDF]

				A. Ascherio and C. M. Tanner USE OF ANTIHYPERTENSIVES AND THE RISK OF PARKINSON DISEASE Neurology, February 10, 2009; 72(6): 578 - 579. [Full Text] [PDF]

				C. Becker, G. P. Brobert, S. Johansson, S. S. Jick, and C. R. Meier Diabetes in Patients With Idiopathic Parkinson's Disease Diabetes Care, September 1, 2008; 31(9): 1808 - 1812. [Abstract] [Full Text] [PDF]

				C. Becker, S. S. Jick, and C. R. Meier Use of antihypertensives and the risk of Parkinson disease Neurology, April 15, 2008; 70(16_Part_2): 1438 - 1444. [Abstract] [Full Text] [PDF]

				A. D. Wahner, J. M. Bronstein, Y. M. Bordelon, and B. Ritz Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease Neurology, November 6, 2007; 69(19): 1836 - 1842. [Abstract] [Full Text] [PDF]

				A. Alonso, L. A. G. Rodriguez, G. Logroscino, and M. A. Hernan Gout and risk of Parkinson disease: A prospective study Neurology, October 23, 2007; 69(17): 1696 - 1700. [Abstract] [Full Text] [PDF]

				D. B. Hancock, E. R. Martin, J. M. Stajich, R. Jewett, M. A. Stacy, B. L. Scott, J. M. Vance, and W. K. Scott Smoking, Caffeine, and Nonsteroidal Anti-inflammatory Drugs in Families With Parkinson Disease Arch Neurol, April 1, 2007; 64(4): 576 - 580. [Abstract] [Full Text] [PDF]